Change in Frequency and Predictors of Erectile Dysfunction With Changes in the International Index of Erectile Function-Erectile Function Domain Score in Patients With ST-Elevation Myocardial Infarction: A Prospective, Longitudinal Study

2020 ◽  
Vol 17 (6) ◽  
pp. 1101-1108
Author(s):  
Emre Karabay ◽  
Nejdet Karsiyakali ◽  
Goksel Cinier ◽  
Gonul Zeren ◽  
Serdar Duvar ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Erectile Dysfunction ◽  
Longitudinal Study ◽  
Erectile Function ◽  
St Elevation Myocardial Infarction ◽  
Domain Score ◽  
Prospective Longitudinal Study ◽  
St Elevation ◽  
Function Domain ◽  
Prospective Longitudinal

scholarly journals Comparison between primary angioplasty and thrombolytic therapy on erectile dysfunction after acute ST elevation myocardial infarction

2012 ◽  
Vol 14 (5) ◽  
pp. 784-787 ◽  
Author(s):  
Ramazan Akdemir ◽  
Özlem Karakurt ◽  
Salih Orcan ◽  
Nihat Karakoyunlu ◽  
Mustafa Mucahit Balci ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Erectile Dysfunction ◽  
Thrombolytic Therapy ◽  
Primary Angioplasty ◽  
St Elevation Myocardial Infarction ◽  
St Elevation

scholarly journals Impact of Testosterone Therapy on hypogonadal patients unresponsive to phosphodiesterase-5 inhibitors alone: A systematic review and a meta-analysis

2021 ◽  
Author(s):  
Xiaowei Yu ◽  
Yanhong Liu ◽  
Xiaoyuan Zhang ◽  
Qun Wang
Keyword(s):  
Erectile Dysfunction ◽  
Treatment Group ◽  
Erectile Function ◽  
Domain Score ◽  
Cochrane Library ◽  
Testosterone Therapy ◽  
Phosphodiesterase 5 Inhibitors ◽  
Function Domain ◽  
Phosphodiesterase 5 ◽  
Dual Treatment

Abstract Background Phosphodiesterase-5 inhibitors as the first-line treatment for erectile dysfunction, when patients with hypogonadism fail to respond to phosphodiesterase-5 inhibitors, the beneficial of addition testosterone therapy is a major concern for clinicians. The objective of this study was to collect and summarize the evidence that evaluated the benefit of addition testosterone therapy in hypogonadism fail to respond to phosphodiesterase-5 inhibitors. Methods Electronic literature searches of Cochrane Library, PubMed, MEDLINE and EMBASE databases were conducted up to October 2020 and included randomized controlled trials. Specifically, we were looking for papers where Erectile Function Domain Score differences between pre and post-treatment were used as the primary outcome after treatment of testosterone therapy alone, phosphodiesterase-5 inhibitors therapy alone, or a dual treatment of both testosterone therapy and phosphodiesterase-5 inhibitors. Secondary outcomes included the number of phosphodiesterase-5 inhibitors non-responders who subsequently reported a satisfactory treatment of dual treatment with testosterone therapy and phosphodiesterase-5 inhibitors. Results A total of 4 studies that met our criteria, consisting of 326 patients. The Erectile Function Domain Score was significantly higher after treatment of testosterone combine with phosphodiesterase-5 inhibitors(4.88[4.18–5.57]), phosphodiesterase-5 inhibitors with placebo(3.15[1.82–4.47]), and testosterone monotherapy (2.04[0.38–3.71]) compared with baseline. Dual treatment with testosterone and phosphodiesterase-5 inhibitors significantly improved Erectile Function Domain Score when compared with testosterone monotherapy (3.16, 95% CI: 1.79–4.53), Of 41.7% patients in the dual treatment group reported an improvement, compared to only 33.0% in phosphodiesterase-5 inhibitors treatment group. Conclusions Combination therapy of testosterone and phosphodiesterase-5 inhibitors seems most effective in men with both erectile dysfunction and hypogonadism who initial unrespond to phosphodiesterase-5 inhibitors.

scholarly journals The Multi-Ethnic New Zealand Study of Acute Coronary Syndromes (MENZACS): Design and Methodology

2021 ◽  
Vol 11 (2) ◽  
pp. 84-97
Author(s):  
Malcolm. E. Legget ◽  
Vicky. A. Cameron ◽  
Katrina. K. Poppe ◽  
Sara Aish ◽  
Nikki Earle ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Coronary Syndrome ◽  
New Zealand ◽  
Acute Coronary Syndromes ◽  
St Elevation Myocardial Infarction ◽  
Coronary Syndrome ◽  
Coronary Syndromes ◽  
St Elevation ◽  
Prospective Longitudinal ◽  
First Time

Background. Each year, approximately 5000 New Zealanders are admitted to hospital with first-time acute coronary syndrome (ACS). The Multi-Ethnic New Zealand Study of Acute Coronary Syndromes (MENZACS) is a prospective longitudinal cohort study embedded within the All New Zealand Acute Coronary Syndrome Quality Improvement (ANZACS-QI) registry in six hospitals. The objective of MENZACS is to examine the relationship between clinical, genomic, and cardiometabolic markers in relation to presentation and outcomes post-ACS. Methods. Patients with first-time ACS are enrolled and study-specific research data is collected alongside the ANZACS-QI registry. The research blood samples are stored for future genetic/biomarker assays. Dietary information is collected with a food frequency questionnaire and information about physical activity, smoking, and stress is also collected via questionnaire. Detailed family history, ancestry, and ethnicity data are recorded on all participants. Results. During the period between 2015 and 2019, there were 2015 patients enrolled. The mean age was 61 years, with 60% of patients aged <65 years and 21% were female. Ethnicity and cardiovascular (CV) risk factor distribution was similar to ANZACS-QI: 13% Māori, 5% Pacific, 5% Indian, and 74% NZ European. In terms of CV risk factors, 56% were ex-/current smokers, 42% had hypertension, and 19% had diabetes. ACS subtype was ST elevation myocardial infarction (STEMI) in 41%, non-ST elevation myocardial infarction (NSTEM) in 54%, and unstable angina in 5%. Ninety-nine percent of MENZACS participants underwent coronary angiography and 90% had revascularization; there were high rates of prescription of secondary prevention medications upon discharge from hospital. Conclusion. MENZACS represents a cohort with optimal contemporary management and will be a significant epidemiological bioresource for the study of environmental and genetic factors contributing to ACS in New Zealand’s multi-ethnic environment. The study will utilise clinical, nutritional, lifestyle, genomic, and biomarker analyses to explore factors influencing the progression of coronary disease and develop risk prediction models for health outcomes.

144: A Prospective Longitudinal Study of Quality of Life Following Radical Perineal Prostatectomy

2004 ◽  
Vol 171 (4S) ◽  
pp. 38-38
Author(s):  
Benjamin K. Yang ◽  
Matthew D. Young ◽  
Brian Calingaert ◽  
Johannes Vieweg ◽  
Brian C. Murphy ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Longitudinal Study ◽  
Prospective Longitudinal Study ◽  
Perineal Prostatectomy ◽  
Prospective Longitudinal

Abdominaler Tumor nach anhaltendem Husten und entgleister Antikoagulation

Praxis ◽  
2010 ◽  
Vol 99 (1) ◽  
pp. 55-59
Author(s):  
Wandeler-Meyer ◽  
Bremerich ◽  
Christ
Keyword(s):  
Myocardial Infarction ◽  
St Elevation Myocardial Infarction ◽  
Diagnostik Und Therapie ◽  
St Elevation

Wir berichten über eine 83-jährige Patientin mit einem STEMI (ST elevation myocardial infarction), welche unter der Thrombozytenaggregationshemmung und systemischen Antikoagulation ein Rektusscheidenhämatom nach einer Hustenattacke entwickelte. Die Patientin beklagte progrediente Schmerzen im linken Unterbauch, welche mit einer palpablen Raumforderung einhergingen und von einer Anämie begleitet waren. In der Abdomensonographie und der Computertomographie zeigte sich ein Rektusscheidenhämatom. Der Artikel erörtert Pathogenese, Klinik, Diagnostik und Therapie unter Berücksichtigung der aktuellen Literatur.

Sign in / Sign up

Export Citation Format

Share Document